B-RAF with PLX4032
From Proteopedia
(Difference between revisions)
| Line 13: | Line 13: | ||
<scene name='B-RAF_with_PLX4032/Phe_595_dfg_out/1'>DFG out</scene><br> | <scene name='B-RAF_with_PLX4032/Phe_595_dfg_out/1'>DFG out</scene><br> | ||
<scene name='B-RAF_with_PLX4032/Superposition3og71uwh/1'>Superposition</scene> <br> | <scene name='B-RAF_with_PLX4032/Superposition3og71uwh/1'>Superposition</scene> <br> | ||
| - | <scene name='B-RAF_with_PLX4032/Confirmation_change_dfg-in/1'> | + | <scene name='B-RAF_with_PLX4032/Confirmation_change_dfg-in/1'>Confirmation Change DFG-In</scene> |
<applet load='3og7' size='700' color='white' frame='true' align='center' caption='testcaption' /> | <applet load='3og7' size='700' color='white' frame='true' align='center' caption='testcaption' /> | ||
Revision as of 13:06, 6 October 2010
B-RAF with PLX4032
PLX4032 is a newly synthesized drug that is being used to treat malignant melanoma with a specific mutation. The mutation is B-RAF^(V600E). This drug is highly selective for this mutation and will not bind to wild type B-RAF.
|
